Various phase I clinical trials investigating CD7-targeting CAR-T cells are recruiting patients with T-cell hematological malignancies including T-ALL and are ongoing (NCT03690011, NCT04004637, NCT04860817, and NCT04620655). The gene discussed is CD7; the disease is acute lymphoblastic leukemia.